Page 2 - Abbott India

Goa state warns Abbott India on antacid Digene license suspension

The state authorities have given Abbott seven days to respond to the notice to defend its position

Abbott India recalls batches of Antacid Digene gel

In its letter, the DCGI warned that Digene may be unsafe and its use may result in adverse reaction

Abbott recalls antacid Digene Gel made in Goa after consumer complaints

India's drugs regulator issues advisory against use; company says there is no 'health concern'

Abbott India posts 41% rise in Q1 profit at Rs 29 crore on strong sales

The company has reported a double-digit growth in its revenue for the past three quarters, led by falling operating expenses and steady sales

Stocks to watch: Wipro, HUL, Axis Bank, Bajaj Finance, Tata Power, Abbott

Stocks to watch today: From Hindustan Unilever to Wipro, here are top stocks to watch in Thursday's trading session

5 mid-cap stocks hit crucial peaks, enter next bull run; Do you own any?

These 5 mid-cap stocks may rise up to 20 per cent, as technical charts reveal positive breakouts

Key brands, new launches to sustain Abbott India's outperformance

Margins to remain healthy on the back of cost-saving measures

Measuring worth: Front-row seats to high return-on-equity stocks

A portfolio of richly valued RoE stocks is expected to outperform the broader market over the longer term.

Core brands, new launches to help Abbott India stock outperform: Analysts

Analysts expect double-digit growth for pharma major even if Q1 disappointed

Pharma company Abbott ties up with health tech firms for diabetes care

Abbott on Tuesday said it has tied up with health-tech firms like BeatO, Sugar.fit, PharmEasy, GOQii, 1MG and Zyla for diabetes care

Strong growth rates expected to drive Abbott India's outperformance

New launches, power brands, digital initiatives to keep it ahead of peers

Abbott introduces single-dose formulation of carbetocin in India

Drug major Abbott on Tuesday said it has launched room-temperature-stable, single-dose formulation of carbetocin in India to help in the prevention of postpartum haemorrhage (PPH)

Abbott gets DCGI nod for once-a-day heart failure, angina treatment drug

Global healthcare firm Abbott on Wednesday said it has received approval from the Drugs Controller General of India (DCGI) for its once-a-day formulation, Ivabradine, used for treatment of chronic heart failure and chronic stable angina. The company plans to launch Ivabradine prolonged release tablets in the Indian market in the coming weeks, Abbott said in a statement. This formulation will be more convenient for patients, which will help facilitate treatment adherence with the aim to improve health outcomes, it added. The formulation has been developed at Abbott's innovation & development (I&D) centre in Mumbai, the statement said. "Adherence to therapy is a critical factor to maximize the overall health of people with chronic heart failure or chronic stable angina. We have used the best technology and science to develop this new dosage formulation," Abbott Regional Medical Director Balagopal Nair said. The convenient once-a-day formulation will help improve overall ...

Nifty may resume downtrend if it breaks below 11,350: HDFC Securities

The recent high of 11,794 would continue to act as strong resistance for the Nifty

Abbott India: More branded products, new launches, volumes to aid gains

The company outperformed most of its peers with a 6 per cent growth in revenues and a 450 basis points y-o-y expansion in operating profit margins

11,250 crucial for Nifty to negate bearish set-up: Vinay Rajani of HDFC Sec

This sharp recovery could end up being a dead cat bounce, as the trend-line support which was recently broken could act as a resistance at 11,250

Indices gain for 2nd day in a row, Sensex up 429 pts; India VIX drops 6%

All that happened in the markets today

Abbott India, Pfizer, L&T Infotech: 11 stocks that may enter F&O segment

The eligibility of stock inclusion in the derivatives / F&O segment is based on the criteria laid down by market regulator Sebi.

New launches could spur growth at Abbott India, near-term headwinds weigh

Upsides are limited for the stock, which has gained over 90% in a year

Near-term hiccups to have limited impact on Abbott India's growth: Experts

Despite the muted result and near term worries, the multinational drug major, India's second largest by market share is expected to post strong growth led by power brands and new launches